Relationship Between Migraine and Alzheimer's Disease: A Study of Mendelian Randomization
Abstract
Background: Given inconsistent evidence regarding the migraine-Alzheimer's disease association, this Mendelian randomization (MR) study examines their potential causal relationship.
Methods: GWAS summary statistics for migraine and Alzheimer's disease were acquired from the IEU Open GWAS repository. We implemented a multi-stage MR framework comprising (1) univariate analysis, (2) independent replication, (3) multivariable MR, (4) meta-analysis to evaluate migraine-AD causality.
Results: Univariate results showed OR = 13.43, 95% CI: 2.86-63.16, P < 0.01; replication Mendelian randomization results were OR = 12.64, 2.89-55.38, P < 0.01 with OR = 1.13, 95% CI: 1.06-1.21, P < 0.01, meta-analysis results were OR = 1.14, 95% CI: 1.07- 1.22, P < 0.01. Multivariate Mendelian randomization results were OR = 18.90, 95% CI: 1.69-210.88, P < 0.01.
Conclusion: Considering the observed epidemiological correlations and shared pathophysiological mechanisms between migraine and Alzheimer's disease (AD), we propose that chronic migraine may increase the susceptibility to AD through complex biological interactions. This hypothesis is reinforced by our Mendelian randomization (MR) findings, which support a causal relationship. Therefore, early and effective intervention in migraine management could serve as a promising strategy to mitigate the future risk of AD onset.
How strong is the evidence?
Evidence Hub reads this as a meta-analysis, done in people. Its evidence level is 1 of 5 (Highest · pooled evidence). Pooled evidence from several studies sits at the top of the evidence pyramid.
Read the paper
Related studies
- Calcium Ions in the Physiology and Pathology of the Central Nervous System
- AI-powered in silico twins: redefining precision medicine through simulation, personalization, and predictive healthcare
- In silico functional, structural and pathogenicity analysis of missense single nucleotide polymorphisms in human MCM6 gene
- In Silico drug repurposing pipeline using deep learning and structure based approaches in epilepsy
- Targeting serotonin receptors with phytochemicals – an in-silico study
- In silico exploration of anti-prostate cancer compounds from differential expressed genes
Go deeper in Evidence Hub
Evidence Hub adds a study data sheet (design, sample size, evidence level, key numbers), an AI summary and a chat grounded in the paper's text.